Xiping Luo

Dr. Xiping Luo


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Infection and Public Health
Verified
Journal Article
Open access
MLMeijuan Li
Meijuan Li
TLTingyan Liu
Tingyan Liu
GLGanfeng Luo
Ganfeng Luo
XSXiaoli Sun
Xiaoli Sun
GHGuiying Hu
Guiying Hu
XLXiping Luo
Xiping Luo
Previous studies showed the incidence, persistence and clearance of cervical human papillomavirus (HPV) among women varies from regions. There is no study on dynamic changes of HPV infection among women in Guangdong. It is a retrospective cohort study that included gynecological outpatients aged ≥15 years and retested for HPV within 24 months in Guangdong Women and Children Hospital to estimate HPV incidence, persistence and clearance. Outcomes were estimated through the proportion of HPV incidence, persistence and clearance in HPV-negative or HPV-positive women. Moreover, we examined HPV incidence, persistence and clearance among women who retested in four calendar periods: 0-6, 6-12, 12-18, 18-24 months after the first test. 33,328 gynecological outpatients were included in our study. Incidence rates of any HPV, high-risk (HR) HPV and low-risk (LR) HPV were 10.58%, 8.68% and 4.83%. The most common incident HR HPV were HPV52 (2.69%), HPV16 (1.23%) and HPV58 (1.23%). Persistence rates of any HPV, HR HPV and LR HPV were 47.55%, 42.77% and 33.88%. HPV52 (42.33%), HPV58 (40.74%) and HPV68 (32.36%) were commonly found persistent types. And clearance rates of any HPV, HR HPV and LR HPV were 52.44%, 57.23% and 66.12%.The lowest clearance rates were observed for HPV52 (57.67%), HPV68 (67.64%) and HPV39 (68.56%). HPV incidence and persistence were higher among women aged 15-19 years and ≥55 years. HPV incidence and persistence were found higher among women who retested within 6 months than others in other periods. HPV52, 58, 68, and 39 were the more likely to cause incident and persistent infection, and less likely to be cleared among women in Guangdong. HPV incidence and persistent infection were higher among women aged both younger and older women compared to middle aged women. HPV retesting period may impact the detection of HPV incidence, persistence and clearance.

29 November 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
QBQiaowen Bu
Qiaowen Bu
SWSanfeng Wang
Sanfeng Wang
JMJian Ma
Jian Ma
XZXiangcheng Zhou
Xiangcheng Zhou
GHGuiying Hu
Guiying Hu
XLXiping Luo
Xiping Luo
To explore the diagnostic value of FAM19A4 methylation in high-risk human papilloma virus (hrHPV)-positive cervical samples from Chinese women for estimating cervical cancer or its precancerous lesions. Cervical samples from 215 women infected with high-risk HPV were collected by smear testing. We purposely chose 61 patients with cervical cancer, 57 with high-grade squamous intraepithelial lesions (HSIL), 31 with low-grade squamous intraepithelial lesions (LSIL), and 66 without cervical intraepithelial neoplasia (CIN) after histological confirmation. Taqman probe-based quantitative PCR (qPCR) was utilized to detect the methylation status of FAM19A4 in the cervical samples and further evaluate the use of this gene in the diagnosis of cervical cancer. (1) An increasing level of FAM19A4 methylation was detected with increasing progression of cervical lesions, with methylation rates of 10.61%(7/66), 35.48%(11/31), 56.14%(32/57) and 93.44%(57/61) in no CIN, LSIL, HSIL and cervical carcinoma samples respectively. (2) In all hrHPV-positive samples, the levels of FAM19A4 methylation in HPV16/18 groups were higher than that in 12 other hrHPV groups (P < 0.05), but there was no significant difference between two groups after grouping cervical lesions into cervical cancer, HSIL, LSIL and no CIN groups (P>0.05). (3)There were no significant differences of FAM19A4 methylation in different clinicopathological parameters of cervical cancer. (4) Though the sensitivity of FAM19A4 methylation test was inferior to that of cytology and FAM19A4 combining with HPV16/18 genotyping, but showed the best specificity with 81.44% both for detection HSIL alone and ≥ HSIL, with favorable youden index (YI) and area under curve (AUC). FAM19A4 is a specific biomarker of cancerous lesions of the cervix. FAM19A4 methylation analysis may serve as an auxiliary screening method for diagnosis of cervical (pre)cancer. However, in consideration of the limitations of this retrospective study, prospective population-based studies are necessary for further confirmation of the diagnostic value of FAM19A4 methylation for detection of cervical (pre)cancer in Chinese women.

17 June 2019 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
GLGanfeng Luo
Ganfeng Luo
XSXiaoli Sun
Xiaoli Sun
MLMeijuan Li
Meijuan Li
TLTingyan Liu
Tingyan Liu
GHGuiying Hu
Guiying Hu
XLXiping Luo
Xiping Luo

9 June 2025 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
HPHaiyu Pang
Haiyu Pang
JLJingyi Liu
Jingyi Liu
QLQing Liu
Qing Liu
LWLuwen Wang
Luwen Wang
HJHangmei Jin
Hangmei Jin
LZLan Zhu
Lan Zhu

29 April 2020 in Research Square
Verified
Preprint
Open access
PDF file
QBQiaowen Bu
Qiaowen Bu
HWHeng-Ying Wu
Heng-Ying Wu
SWSan-Feng Wang
San-Feng Wang
JMJian Ma
Jian Ma
WLWen Lei
Wen Lei
XLXiping Luo
Xiping Luo
BackgroundAberrant Septin9 methylation in cervical cancer has been rarely studied. In this study we aimed to identify its diagnostic value of cervical cancer in cervical scrapings, and its predictive potential in plasma for pelvic nodal metastasis of cervical cancer.MethodsThe statuses of methylated Septin9 in fresh cervical lesions were first evaluated by using quantitative methylation-specific PCR(qMS-PCR). Subsequently 248 samples of cervical scrapings were collected to explore Septin9 methylation in different severities of cervical lesions; and the relationship between Septin9 methylation in plasma and pelvic nodal metastasis of cervical cancer was further evaluated.ResultsMethylated Septin9 was detected in all cancerous tissues, but not in cervicitis controls (P < 0.0001). The degrees of Septin9 methylation increased with growing severity of cervical lesions in cervical scrapings (P < 0.0001). Methylation analysis of Septin9 demonstrated a satisfactory specificity and area under the curve(AUC) in cervical cancer detection, at an equivalent sensitivity relative to any other test. And methylated Septin9 also yielded a high specificity and AUC in detecting high-grade squamous intraepithelial lesion or cervical cancer(≥ HSIL). Plasma-based Septin9 methylation had a high discriminatory power in predicting pelvic nodal metastasis, with an optimal specificity of 81.48%; additionally an increasing sensitivity from 50% to nearly 80% was found when combined with squamous cell carcinoma antigen(SCC-Ag). ConclusionsIn conclusion, we demonstrated methylated Septin9 to be an innovative diagnostic biomarker for cervical cancer in cervical scrapings and its non-invasive predictive potential in plasma for pelvic nodal metastasis of cervical cancer.

17 December 2025 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
LWLi Wang
Li Wang
LXLingling Xie
Lingling Xie
QLQingshui Li
Qingshui Li
YSYang Shen
Yang Shen
HWHuaying Wang
Huaying Wang
ZLZhongqiu Lin
Zhongqiu Lin
Background: Ovarian cancer (OC) is a highly lethal gynecological cancer. Olaparib maintenance therapy was effective and well-tolerated in pivotal RCTs. However, nationwide real-world safety information is limited in China. This multicenter, prospective, observational drug intensive monitoring study monitored the safety of olaparib in a largest-to-date, real-world Chinese OC cohort. Methods: Eligible OC patients had received ≥ 1 dose of olaparib. Follow-up extended up to 30 days post-olaparib discontinuation or maximally for six months post-enrolment. Primary and secondary endpoints were adverse events (AEs) in all OC patients and in special populations (hepatically/renally impaired before olaparib treatment; aged > 65 years), respectively. Results: By Jun 30, 2023, 799 patients from 33 sites were enrolled. By data cut-off (Dec 29, 2023), 796 patients treated with olaparib were analyzed. The median age was 55 years (range, 25–85). Of 796 patients, 490 (61.6%) were newly diagnosed and 306 (38.4%) had platinum-sensitive relapsed OC. AEs occurred in 343 (43.1%) patients, and 257 (32.3%) had treatment-related AEs. Anemia (19.2%) was the most common AE. Sixty-eight (8.5%) patients experienced grade ≥ 3 AEs, and 3 had AEs of special interest (AESIs; 0.4%; 1 myelodysplastic syndrome, 1 breast cancer, 1 pneumonitis). 45.2% (19/42) patients with hepatic impairment at baseline, 38.5% (5/13) with renal impairment at baseline and 38.6% (49/127) aged > 65 years experienced any AEs, respectively. No AESIs were reported in these subgroups. Conclusions: In this largest-to-date, first prospectively enrolled, real-world Chinese OC cohort, olaparib demonstrated a well-tolerated and manageable safety profile (including in special populations) with appropriate management, regardless of treatment lines. No new safety signals were identified.